Helmholtz Munich and Pfizer seek to achieve three primary objectives:
Accelerate Target Discovery
By amalgamating Pfizer's wealth of knowledge and data with Helmholtz Munich's proficiency in novel machine learning methods, the collaboration aims to expedite target discovery. This involves choosing genes and compounds for validation based on predicted molecular traits, discovering new targets, and finding opportunities for combination therapies.
Inform Precision Medicine
Integrating omics data from Pfizer's clinical assets and applying innovative and interpretable deep learning techniques will inform precision medicine. This step will enhance the understanding of individualized patient responses and pave the way for more effective and targeted treatment strategies.
Facilitate Preclinical to Clinical Translation
The collaboration aspires to bridge the gap between preclinical research and clinical applications. The partners want to use advanced machine learning methods to map preclinical and clinical samples in a latent space where samples close to each other share similar characteristics such as gene expression profiles and biological pathways.
“Our department’s vision towards an AI-supported precision medicine is showcased through our innovative deep-learning approaches and ability to harness data-driven insights. We are excited to collaborate with Pfizer to discover new targets and seamlessly translate these insights from preclinical stages to clinical applications.”
Fabian Theis, Head of the Computational Health Center at Helmholtz Munich
Scope and Funding
The collaboration is set to span three years, during which Pfizer will fund a dedicated team at the Helmholtz Munich Computational Health Center. “Helmholtz Munich is at the forefront of computational health research. This investment underscores our commitment to fostering innovation and advancing the frontiers of healthcare through the convergence of pharmaceutical expertise and cutting-edge computational methodologies,” says Jie Quan, Director of Computational Systems Immunology at Pfizer Inc.
